Stocks
Corvus Pharmaceuticals, Inc.CRVS
NASDAQHealthcareBiotechnology$10.53
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing novel immunotherapies for cancer and autoimmune diseases. Its lead candidate, sobetirome, is in Phase 3 trials for T-cell lymphoma, with additional programs in solid tumors and atopic dermatitis. Investors track CRVS for its potential first-in-class oral therapy and upcoming clinical data readouts.
52W Range: $6.39-$26.95
Congressional Interest in Corvus Pharmaceuticals, Inc. (CRVS)
No congressional trades have been disclosed for Corvus Pharmaceuticals, Inc. (CRVS) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading CRVS?
No congressional trades found for this stock.